Parameter
- 406 Seiten
- 15 Lesestunden
Mehr zum Buch
Volume 41 of "Progress in Orug Research" features eight reviews and various indexes that enhance usability and connect with prior volumes. The articles cover diverse topics, including teratogenesis, nephrotoxicity, bacterial resistance to P. lactam antibiotics, disease eradication through vaccination, chirality in drug design, endogenous digitalis-like factors, erythropoietin, and serotonin (5HT)-antagonists. Each article provides a comprehensive overview of its respective research field. Over its 33-year history, the Editor has benefited from the support and insights of numerous colleagues, with contributions from readers, authors, and reviewers significantly enhancing the series' success. While feedback has generally been positive, it remains essential to evaluate the current status and future trajectory of the review series. The Editor aims to disseminate information across the broad spectrum of drug research, offering readers a means to stay updated on the latest advancements and trends. The reviews are particularly beneficial for non-specialists seeking a quick understanding of specific research areas, while specialists will value the extensive bibliographies and may find new inspiration for their own work.
Buchkauf
Progress in Drug Research, Volume 41, Ernst Jucker
- Sprache
- Erscheinungsdatum
- 1993
- product-detail.submit-box.info.binding
- (Hardcover)
Keiner hat bisher bewertet.
- Titel
- Progress in Drug Research, Volume 41
- Untertitel
- Progress in Drug Research / ...
- Sprache
- Englisch
- Autor*innen
- Ernst Jucker
- Verlag
- Springer
- Erscheinungsdatum
- 1993
- Einband
- Hardcover
- Seitenzahl
- 406
- ISBN10
- 3764329254
- ISBN13
- 9783764329259
- Reihe
- Schlagwörter
- Beschreibung
- Volume 41 of "Progress in Orug Research" features eight reviews and various indexes that enhance usability and connect with prior volumes. The articles cover diverse topics, including teratogenesis, nephrotoxicity, bacterial resistance to P. lactam antibiotics, disease eradication through vaccination, chirality in drug design, endogenous digitalis-like factors, erythropoietin, and serotonin (5HT)-antagonists. Each article provides a comprehensive overview of its respective research field. Over its 33-year history, the Editor has benefited from the support and insights of numerous colleagues, with contributions from readers, authors, and reviewers significantly enhancing the series' success. While feedback has generally been positive, it remains essential to evaluate the current status and future trajectory of the review series. The Editor aims to disseminate information across the broad spectrum of drug research, offering readers a means to stay updated on the latest advancements and trends. The reviews are particularly beneficial for non-specialists seeking a quick understanding of specific research areas, while specialists will value the extensive bibliographies and may find new inspiration for their own work.